Vaccine Immunology Program

$6,901,965ZIAFY2025AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Paper 38873606 Paper 38773089 Paper 38717904 Paper 38704686 Paper 38669354 Paper 38587079 Paper 38517951 Paper 38430907 Paper 38318357 Paper 38170789 Paper 37554450 Paper 37544326 Paper 37436900 Paper 37436899 Paper 37345226 Paper 37098956 Paper 37075129 Paper 37075126 Paper 36709074 Paper 36599369 Paper 35921449 Paper 35783486 Paper 35589938 Paper 35489332 Paper 35411076 Paper 35233581 Paper 35115707 Paper 35115706 Paper 35036969 Paper 34562096 Paper 34213402 Paper 33880468 Paper 33826898 Paper 33822494 Paper 33755731 Paper 33741916 Paper 33720905 Paper 33688652 Paper 33662277 Paper 33661303 Paper 33655252 Paper 33582148 Paper 33536277 Paper 33495459 Paper 33493795 Paper 33442707 Paper 33270381 Paper 32866318 Paper 32755575 Paper 32619441 Paper 32353250 Paper 32330555 Paper 32295908 Paper 32034141 Paper 32015557 Paper 31473167 Paper 31350180 Paper 31213541 Paper 31004012 Paper 31000477 Paper 30980067 Paper 30971821 Paper 30876875 Paper 30808695 Paper 30686586 Paper 30517201 Paper 29867235 Paper 29664020 Paper 29554083 Paper 29444938 Paper 29364886 Paper 29237774 Paper 28663207

Abstract

The Vaccine Immunology Program is responsible for the end point analyses of clinical vaccine, antibody therapeutic and prevention trials carried out by the Vaccine Research Center or in collaboration with intramural and extramural investigators. In addition, the VIP investigates basic B cell immunobiology to elucidate the mechanisms that inform the discovery and development of vaccines for public health, including HIV, Influenza, Ebola, Malaria, TB, in addition to other emerging and re-emerging infectious diseases. This involves development of sophisticated and high-throughput analyses that supports in-depth investigation of clinical trials, including highly qualified clinical assays for use in pre-clinical evaluation, IND submissions, for product licensure, and to evaluate trial endpoints.

View original record on NIH RePORTER →